SAN JOSE, Calif./PRNewswire/ -- The CyberKnife Society, a non-profit organization of medical professionals dedicated to advancing the science and clinical practice of radiosurgery, announced highlights from its 2010 CyberKnife Society Scientific Meeting, which was held March 26-27, 2010 at The Fairmont Dallas in downtown Dallas, Texas.

This year's CyberKnife Scientific Meeting featured more than 60 clinical and 25 technical presentations and posters selected by a scientific panel of users. Presentations from CyberKnife users worldwide focused on a wide spectrum of applications, including brain, spine, lung, breast, prostate, kidney, liver, pancreas, lymph nodes, and head and neck, demonstrating the vast capabilities and mainstream market acceptance of the CyberKnife System.

"The quality of the presentations in this scientific meeting shows that full body radiosurgery is maturing and becoming an indispensable tool in the treatment of cancer," said Clinton Medbery, M.D., President of The CyberKnife Society.
Because of the system's unrivaled ability to track and compensate for tumor motion, adoption of CyberKnife radiosurgery for the treatment of lung and prostate cancer continues to grow. This trend was supported by 20 lung and five prostate presentations. The use of radiosurgery, also referred to as SBRT, for the treatment of lung cancer has been a topic of great interest lately and the benefits of delivery using the CyberKnife System were highlighted in presentations on primary, metastatic and recurrent disease. Additionally, CyberKnife prostate data was presented that included patients out as far as five years post-treatment, highlighting some of the longest follow-up to date for prostate radiosurgery.

In addition to updated outcomes and longer follow-up for extracranial applications, users continue to extend the advantages of the CyberKnife System for the treatment of intracranial indications. One of the largest-scale studies presented at this year's meeting was on experience treating more than 500 patients with brain metastases.

"The wide range of clinical and technical presentations is a testament to the growing use and established capabilities of the CyberKnife System," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray. "The system's unique combination of continual image guidance, intelligent robotics and best-in-class motion management is what has made the CyberKnife System the most trusted device for radiosurgical treatment throughout the body."

More HCB News